Evidence map›Paper›PMID 24665207›Full record

ArticleCancer growth and metastasis2013

Enhancing Cancer Drug Discovery through Novel Cell Signaling Pathway Panel Strategy.

Liang Schweizer, Litao Zhang

Abstract read
In one paragraph

Article in Cancer growth and metastasis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Liang SchweizerLead Evaluation and Mechanistic Biochemistry, Bristol Myers Squibb Company, Princeton, NJ.
Litao ZhangLead Evaluation and Mechanistic Biochemistry, Bristol Myers Squibb Company, Princeton, NJ.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The link between signaling pathways and diseases suggests the importance of pathway analysis for drug discovery. This includes target identification and validation, compound mode of action and drug candidate optimization. Here, we propose to apply cell signaling pathway panel approaches for oncology drug discovery. The strategies and guiding principles of the pathway panel approach are discussed. 2 pathway analysis examples with related processes and technology platforms are illustrated to identify cancer drugs that target cancer growth and metastasis. Finally, we highlight potential challenges and opportunities presented by the pathway panel approach.

Indexed as

apoptosisdrug discoveryoncologypathway paneltechnology platformWnt signaling

Identifiers

PMID24665207
PMCPMC3941151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.